دورية أكاديمية
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
| العنوان: | Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. |
|---|---|
| المؤلفون: | Devos T., Verhoef G., Steel E., Mazure D., Lewalle P., Bron D., Berneman Z., Benghiat FS., MIneur P., Theunissen K., Zachée P., Doyen C., Put N., LEJEUNE, Marie, Van Eygen K., Havelange V., Reusens M., Pluymers W., Peeters K. |
| المصدر: | Acta Haematologica, 142 (197-207) (2019) |
| بيانات النشر: | Karger, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Chronic myeloid leukaemia, Tyrosine kinase inhibitor, Treatment interruption/discontinuation, Molecular response, Imatinib, Nilotinib, Dasatinib, Ponatinib, Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients withchronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context)between May 2013 and May 2016. Data collection took placebetween October 2016 and February 2017. Results: All 60participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance(46/69; 67%); other reasons included a wish to conceive(6/69; 9%) and attempts to achieve treatment-free remission(TFR) (6/69; 9%). Interruptions due to side effects occurredlater for imatinib- or dasatinib-treated patients than forthose on nilotinib or ponatinib. Treatment was re-initiated in62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4patients with ≥MR 4.5 at interruption/discontinuation and≥11-month follow-up who had not restarted treatmentmaintained the response. Conclusion: Although TKIs areused for long-term CML treatment, physicians sometimesrecommend interruptions/discontinuations. In this study,interruptions/discontinuations were mainly caused by sideeffects or intolerance, rather than TFR attempts. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article |
| اللغة: | English |
| Relation: | urn:issn:0001-5792; urn:issn:1421-9662 |
| DOI: | 10.1159/000499329 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/255107 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.255107 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1159/000499329 |
|---|